Change in patient‐centered outcomes of psychological well‐being, sleep, and suicidality following treatment with intravenous ketamine for late‐life treatment‐resistant depression
Benjamin Vanderschelden, M. A. Gebara, H. Oughli, M. Butters, Patrick J. Brown, N. Farber, A. Flint, J. Karp, H. Lavretsky, B. Mulsant, C. Reynolds, S. Roose, E. Lenze
International Journal of Geriatric Psychiatry July 1, 2023 DOI: 10.1002/gps.5964 via Semantic Scholar
Summary
Among older adults with treatment-resistant depression, intravenous ketamine treatment was associated with improvements in psychological well-being and sleep, but not in suicidality. The findings suggest that ketamine may enhance aspects of mental health beyond depressive symptoms in this population, though its effect on suicidal thoughts remains unclear.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | Older adults with late-life treatment-resistant depression |
| Keywords | Medicine Psychology |
| Citations | 13 |
| Key finding | Intravenous ketamine improved psychological well-being and sleep but did not improve suicidality in older adults with treatment-resistant depression. |
Abstract
To examine whether psychological well‐being, sleep, and suicidality improved with treatment with intravenous (IV) ketamine for late‐life treatment‐resistant depression (TRD).